MARKET

TECH

TECH

Bio-Techne
NASDAQ

Real-time Quotes | Nasdaq Last Sale

306.58
+7.63
+2.55%
After Hours: 306.58 0 0.00% 16:15 12/04 EST
OPEN
302.25
PREV CLOSE
298.95
HIGH
306.86
LOW
300.63
VOLUME
113.47K
TURNOVER
--
52 WEEK HIGH
316.87
52 WEEK LOW
155.17
MARKET CAP
11.84B
P/E (TTM)
48.82
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development
Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.
PR Newswire · 3d ago
RenalytixAI soars 20% as FDA OK's emergency use of Kantaro's COVID-19 antibody test
Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI (RNLX), has received Emergency Use Authorization ((EUA)) from the FDA for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody
Seekingalpha · 11/25 13:20
RenalytixAI Joint Venture Kantaro Biosciences Receives FDA Emergency Use Authorization ForIts COVID-SeroKlir Semi-Quantitative COVID-19 Antibody Test Kit; Kits Being MAnufactured Through Partnership With Bio-Techne
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ:RNLX), has received Emergency Use Authorization (EUA) from
Benzinga · 11/25 12:37
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
, /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. Unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies and has a broad range of applications in the fight against COVID-19. Through a commercial partnership with Bio-Techne Corporation (NASDAQ: TECH) the test kits are being manufactured at scale with a capacity of up to 10 million tests per month and the ability to scale up.
PR Newswire - PRF · 11/25 12:30
Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies
Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. Unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies and has a broad range of applications in the fight against COVID-19. Through a commercial partnership with Bio-Techne Corporation (NASDAQ: TECH) the test kits are being manufactured at scale with a capacity of up to 10 million tests per month and the ability to scale up.
PR Newswire · 11/25 12:30
Bio-Techne Corp Up 18.4% Since SmarTrend Uptrend Call (TECH)
SmarTrend identified an Uptrend for Bio-Techne Corp (NASDAQ:TECH) on October 6th, 2020 at $255.38. In approximately 2 month, Bio-Techne Corp has returned 18.44% as of today's recent price of $302.47.
Comtex SmarTrend(R) · 11/20 18:13
76 Stocks Trading Ex-Dividend Today, Friday, Nov. 13, 2020:
PFSI, PBFX, SBRA, ALSN, CNS, SBR, AJX, FINS, GLPI, BOKF, AAN, UI, SGC, STK, CHE, REYN, KLAC, CET, ROK, FNHC, KMPR, TECH, BGSF, HAFC, ABC, ACC, GAM, PAAS, HNI, CORR, AIT, SMP, APAM, TCF, LNN, CF, HTH, CHD, DRE, AGCO, OSK,
Benzinga · 11/13 13:02
Bio-Techne To Present At The Stephens Annual Investment Conference 2020
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that , President and Chief Executive Officer, will present at the Stephens Annual Investment Conference 2020 on at . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at .
PR Newswire - PRF · 11/11 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TECH stock price target is 323.56 with a high estimate of 365.00 and a low estimate of 300.00.
EPS
Institutional Holdings
Institutions: 566
Institutional Holdings: 39.44M
% Owned: 102.16%
Shares Outstanding: 38.61M
TypeInstitutionsShares
Increased
149
1.41M
New
80
285.17K
Decreased
139
1.87M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Robert Baumgartner
President/Chief Executive Officer/Director
Charles Kummeth
Chief Financial Officer/Executive Vice President - Finance
James Hippel
Corporate Executive
David Eansor
Corporate Executive
Kim Kelderman
Senior Vice President/General Counsel/Secretary
Brenda Furlow
Independent Director
Julie Bushman
Independent Director
John Higgins
Independent Director
Joseph Keegan
Independent Director
Roeland Nusse
Independent Director
Alpna Seth
Independent Director
Randolph Steer
Independent Director
Rupert Vessey
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
11/05/2020
Dividend USD 0.32
11/13/2020
08/04/2020
Dividend USD 0.32
08/17/2020
04/30/2020
Dividend USD 0.32
05/08/2020
02/04/2020
Dividend USD 0.32
02/13/2020
10/29/2019
Dividend USD 0.32
11/07/2019
08/06/2019
Dividend USD 0.32
08/15/2019
04/30/2019
Dividend USD 0.32
05/09/2019
02/05/2019
Dividend USD 0.32
02/14/2019
--
Dividend USD 0.32
11/08/2018
--
Dividend USD 0.32
08/16/2018
--
Dividend USD 0.32
05/11/2018
--
Dividend USD 0.32
02/15/2018
--
Dividend USD 0.32
11/09/2017
--
Dividend USD 0.32
08/16/2017
--
Dividend USD 0.32
05/17/2017
--
Dividend USD 0.32
02/15/2017
10/31/2016
Dividend USD 0.32
11/09/2016
08/17/2016
Dividend USD 0.32
08/25/2016
04/26/2016
Dividend USD 0.32
05/11/2016
--
Dividend USD 0.32
02/10/2016
--
Dividend USD 0.32
11/10/2015
08/06/2015
Dividend USD 0.32
08/13/2015
05/05/2015
Dividend USD 0.32
05/13/2015
02/03/2015
Dividend USD 0.32
02/11/2015
10/30/2014
Dividend USD 0.32
11/06/2014
08/11/2014
Dividend USD 0.31
08/19/2014
04/28/2014
Dividend USD 0.31
05/07/2014
02/04/2013
Dividend USD 0.31
02/12/2014
10/31/2013
Dividend USD 0.31
11/07/2013
08/06/2013
Dividend USD 0.3
08/14/2013
04/30/2013
Dividend USD 0.3
05/08/2013
02/05/2013
Dividend USD 0.3
02/13/2013
10/26/2012
Dividend USD 0.3
11/01/2012
07/31/2012
Dividend USD 0.28
08/08/2012
05/01/2012
Dividend USD 0.28
05/09/2012
01/31/2012
Dividend USD 0.28
02/08/2012
10/27/2011
Dividend USD 0.28
11/03/2011
08/02/2011
Dividend USD 0.27
08/10/2011
05/03/2011
Dividend USD 0.27
05/11/2011
02/01/2011
Dividend USD 0.27
02/09/2011
10/28/2010
Dividend USD 0.27
11/04/2010
--
Dividend USD 0.26
08/12/2010
05/04/2010
Dividend USD 0.26
05/12/2010
02/02/2010
Dividend USD 0.26
02/10/2010
10/29/2009
Dividend USD 0.26
11/05/2009
08/04/2009
Dividend USD 0.25
08/13/2009
04/28/2009
Dividend USD 0.25
05/06/2009
02/03/2009
Dividend USD 0.25
02/11/2009
10/23/2008
Dividend USD 0.25
10/30/2008
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TECH
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.